Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 405

1.

C-reactive protein, procalcitonin, clinical pulmonary infection score, and pneumonia severity scores in nursing home acquired pneumonia.

Porfyridis I, Georgiadis G, Vogazianos P, Mitis G, Georgiou A.

Respir Care. 2014 Apr;59(4):574-81. doi: 10.4187/respcare.02741. Epub 2013 Oct 8.

2.

Predictive values of semi-quantitative procalcitonin test and common biomarkers for the clinical outcomes of community-acquired pneumonia.

Ugajin M, Yamaki K, Hirasawa N, Yagi T.

Respir Care. 2014 Apr;59(4):564-73. doi: 10.4187/respcare.02807. Epub 2013 Oct 29.

3.

Carboxy-terminal provasopressin may predict prognosis in nursing home acquired pneumonia.

Kim SH, Chung JH, Lee JC, Park YH, Joe JH, Hwang HJ.

Clin Chim Acta. 2013 Jun 5;421:226-9. doi: 10.1016/j.cca.2013.02.022. Epub 2013 Feb 27.

PMID:
23454473
4.

Prognostic value of severity indicators of nursing-home-acquired pneumonia versus community-acquired pneumonia in elderly patients.

Ugajin M, Yamaki K, Hirasawa N, Kobayashi T, Yagi T.

Clin Interv Aging. 2014 Feb 11;9:267-74. doi: 10.2147/CIA.S58682. eCollection 2014.

5.

Sequential measurements of procalcitonin levels in diagnosing ventilator-associated pneumonia.

Ramirez P, Garcia MA, Ferrer M, Aznar J, Valencia M, Sahuquillo JM, Menéndez R, Asenjo MA, Torres A.

Eur Respir J. 2008 Feb;31(2):356-62. Epub 2007 Oct 24.

6.

The value of procalcitonin level in community-acquired pneumonia in the ED.

Park JH, Wee JH, Choi SP, Oh SH.

Am J Emerg Med. 2012 Sep;30(7):1248-54. doi: 10.1016/j.ajem.2011.08.009. Epub 2011 Oct 24.

PMID:
22030193
7.

Validity of severity scores in hospitalized patients with nursing home-acquired pneumonia.

El-Solh AA, Alhajhusain A, Abou Jaoude P, Drinka P.

Chest. 2010 Dec;138(6):1371-6. doi: 10.1378/chest.10-0494. Epub 2010 May 27.

PMID:
20507947
8.

Usefulness of a semi-quantitative procalcitonin test and the A-DROP Japanese prognostic scale for predicting mortality among adults hospitalized with community-acquired pneumonia.

Kasamatsu Y, Yamaguchi T, Kawaguchi T, Tanaka N, Oka H, Nakamura T, Yamagami K, Yoshioka K, Imanishi M.

Respirology. 2012 Feb;17(2):330-6. doi: 10.1111/j.1440-1843.2011.02101.x.

PMID:
22059525
9.

Comparison of diagnostic values of procalcitonin, C-reactive protein and blood neutrophil/lymphocyte ratio levels in predicting bacterial infection in hospitalized patients with acute exacerbations of COPD.

Tanrıverdi H, Örnek T, Erboy F, Altınsoy B, Uygur F, Atalay F, Tor MM.

Wien Klin Wochenschr. 2015 Oct;127(19-20):756-63. doi: 10.1007/s00508-014-0690-6. Epub 2015 Jan 14.

PMID:
25586444
10.

Procalcitonin and C-reactive protein in hospitalized adult patients with community-acquired pneumonia or exacerbation of asthma or COPD.

Bafadhel M, Clark TW, Reid C, Medina MJ, Batham S, Barer MR, Nicholson KG, Brightling CE.

Chest. 2011 Jun;139(6):1410-1418. doi: 10.1378/chest.10-1747. Epub 2010 Oct 28.

11.

Clinical characteristics of nursing home-acquired pneumonia in elderly patients admitted to a Korean teaching hospital.

Koh SJ, Lee JH.

Korean J Intern Med. 2015 Sep;30(5):638-47. doi: 10.3904/kjim.2015.30.5.638. Epub 2015 Aug 27.

12.

The association of serum procalcitonin and high-sensitivity C-reactive protein with pneumonia in elderly multimorbid patients with respiratory symptoms: retrospective cohort study.

Nouvenne A, Ticinesi A, Folesani G, Cerundolo N, Prati B, Morelli I, Guida L, Lauretani F, Maggio M, Aloe R, Lippi G, Meschi T.

BMC Geriatr. 2016 Jan 15;16:16. doi: 10.1186/s12877-016-0192-7.

13.

Outcome of nursing home-acquired pneumonia: derivation and application of a practical model to predict 30 day mortality.

Naughton BJ, Mylotte JM, Tayara A.

J Am Geriatr Soc. 2000 Oct;48(10):1292-9.

PMID:
11037018
14.

Comparison of severity predictive rules for hospitalised nursing home-acquired pneumonia in Korea: a retrospective observational study.

Lee JC, Hwang HJ, Park YH, Joe JH, Chung JH, Kim SH.

Prim Care Respir J. 2013 Jun;22(2):149-54. doi: 10.4104/pcrj.2013.00011.

15.

Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes.

Krüger S, Ewig S, Marre R, Papassotiriou J, Richter K, von Baum H, Suttorp N, Welte T; CAPNETZ Study Group.

Eur Respir J. 2008 Feb;31(2):349-55. Epub 2007 Oct 24.

16.

Utility of two biomarkers for directing care among patients with non-severe community-acquired pneumonia.

España PP, Capelastegui A, Bilbao A, Diez R, Izquierdo F, Lopez de Goicoetxea MJ, Gamazo J, Medel F, Salgado J, Gorostiaga I, Quintana JM; Population Study of Pneumonia (PSoP) Group.

Eur J Clin Microbiol Infect Dis. 2012 Dec;31(12):3397-405. doi: 10.1007/s10096-012-1708-5. Epub 2012 Aug 5.

PMID:
23010902
17.

Prognostic value of procalcitonin in community-acquired pneumonia.

Schuetz P, Suter-Widmer I, Chaudri A, Christ-Crain M, Zimmerli W, Mueller B; Procalcitonin-Guided Antibiotic Therapy and Hospitalisation in Patients with Lower Respiratory Tract Infections (ProHOSP) Study Group.

Eur Respir J. 2011 Feb;37(2):384-92. doi: 10.1183/09031936.00035610. Epub 2010 Jul 1.

18.

Procalcitonin and C-reactive protein in severe 2009 H1N1 influenza infection.

Ingram PR, Inglis T, Moxon D, Speers D.

Intensive Care Med. 2010 Mar;36(3):528-32. doi: 10.1007/s00134-009-1746-3.

PMID:
20069274
19.

Performance of pro-adrenomedullin for identifying adverse outcomes in community-acquired pneumonia.

España PP, Capelastegui A, Mar C, Bilbao A, Quintana JM, Diez R, Esteban C, Bereciartua E, Unanue U, Uranga A.

J Infect. 2015 May;70(5):457-66. doi: 10.1016/j.jinf.2014.12.003. Epub 2014 Dec 11.

PMID:
25499199
20.

Prognostic power of proadrenomedullin in community-acquired pneumonia is independent of aetiology.

Bello S, Lasierra AB, Mincholé E, Fandos S, Ruiz MA, Vera E, de Pablo F, Ferrer M, Menendez R, Torres A.

Eur Respir J. 2012 May;39(5):1144-55. doi: 10.1183/09031936.00080411. Epub 2011 Nov 10.

Supplemental Content

Support Center